CAJ | 학술논문

目的：研究瑞舒伐他汀及阿托伐他汀治疗冠心病的临床疗效及对血管内皮功能的影响。方法将该院于2011年8月-2014年7月收治的92例冠心病患者抽签随机分为观察组与对照组，观察组给予瑞舒伐他汀治疗，对照组阿托伐他汀治疗，比较两组患者治疗前后血脂水平变化及血清NO、hs-CRP、FMD水平。结果治疗后观察组TC、TG、LDL-C分别为(3.76±0.31)、(1.55±0.29)、(2.12±0.22)mmol/L与对照组(5.03±0.46)、(1.93±0.34)、(2.86±0.25)mmol/L比较显著较低(P<0.05)，观察组HDL-C为(1.56±0.30)mmol/L显著高于对照组(1.42±0.22)mmol/L，对比差异有统计学意义(P<0.05)；治疗后观察组NO为(105.25±9.34)μbmol/L与对照组(93.13±8.44)μbmol/L比较显著较高，Hs-CRP(2.16±0.66)mg/L与对照组(3.85±0.60)mg/L比较显著较低(P<0.05)，FMD比较差异无统计学意义(P>0.05)。结论瑞舒伐他汀与阿托伐他汀均为治疗冠心病的有效方式，均可降低血脂水平，缓解炎症反应，提高血管内皮功能，而瑞舒伐他汀效果优于阿托伐他汀，可作为优选方案在临床应用。
목적：연구서서벌타정급아탁벌타정치료관심병적림상료효급대혈관내피공능적영향。방법장해원우2011년8월-2014년7월수치적92례관심병환자추첨수궤분위관찰조여대조조，관찰조급여서서벌타정치료，대조조아탁벌타정치료，비교량조환자치료전후혈지수평변화급혈청NO、hs-CRP、FMD수평。결과치료후관찰조TC、TG、LDL-C분별위(3.76±0.31)、(1.55±0.29)、(2.12±0.22)mmol/L여대조조(5.03±0.46)、(1.93±0.34)、(2.86±0.25)mmol/L비교현저교저(P<0.05)，관찰조HDL-C위(1.56±0.30)mmol/L현저고우대조조(1.42±0.22)mmol/L，대비차이유통계학의의(P<0.05)；치료후관찰조NO위(105.25±9.34)μbmol/L여대조조(93.13±8.44)μbmol/L비교현저교고，Hs-CRP(2.16±0.66)mg/L여대조조(3.85±0.60)mg/L비교현저교저(P<0.05)，FMD비교차이무통계학의의(P>0.05)。결론서서벌타정여아탁벌타정균위치료관심병적유효방식，균가강저혈지수평，완해염증반응，제고혈관내피공능，이서서벌타정효과우우아탁벌타정，가작위우선방안재림상응용。
Objective To study the clinical efficacy of rosuvastatin and atorvastatin in treatment of coronary heart disease and thier effects on vascular endothelial function. Methods 92 cases of coronary heart disease patients from 2011 August to 2014 July were randomly divided into observation group and control group, the observation group was received rosuvastatin treatment, control group was received atorvastatin treatment. Comparison on the changes in blood lipid levels and serum NO, hs-CRP, FMD level of two groups before and after treatment was done. Results After treatment, TC, TG, LDL-C of the observation group, (3.76±0.31) mmol/L, (1.55±0.29) mmol/L, (2.12±0.22) mmol/L were significantly lower than those of the control group (5.03±0.46) mmol/L, (1.93±0.34) mmol/L, (2.86±0.25) mmol/L (P<0.05);HDL-C of the observation group, (1.56±0.30) mmol/L, was significantly higher than that of the control group , (1.42±0.22) mmol/L, the differences were significant (P<0.05);The NO in observation group after treatment (105.25±9.34) bmol/L was significantly higher than that of the control group (93.13±8.44) bmol/L; Hs-CRP (2.16±0.66) mg/L in observation group was significantly lower than that in the control group (3.85±0.60) mg/L (P<0.05), difference of FMD had no statistical significance (P>0.05). Conclusion Rosuvastatin and atorvastatin are effective ways to treat coronary heart disease, both of which can lower the level of blood lipid, alleviate the inflammatory reaction and improve vascular endothelial function. Compared with atorvastatin, the effect of rosuvastatin is better, so it can be used as the preferred scheme in clinical application.